StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) shareholders

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$32.87−1.03 (-3.04%)

Close on Nov 17, 2026Market cap $1.83BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
59M of 56M shares
Institutional holders
162
39 new, 39 sold out
Net institutional buying
10M
In Q2 2026
Insider trades, 12 months
0 buys · 100 sales
Net sold $24.96M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Third Rock Ventures IV, L.P.
Joint filing with Third Rock Ventures GP IV, L.P. (13.90%), Trv Gp Iv, LLC (13.90%)
6,073,95813.90%13G (passive)Jan 31, 2025
Third Rock Ventures GP IV, L.P.
Joint filing with Third Rock Ventures IV, L.P. (9.30%), Trv Gp Iv, LLC (9.30%)
4,473,9589.30%13G (passive) amendmentDec 31, 2025
James N. Topper
Joint filing with Patrick J. Heron (10.20%), Albert Cha (9.70%) and 4 more
4,451,33910.20%13G (passive) amendmentApr 25, 2025
Fhmlsp, L.P.
Joint filing with Frazier Life Sciences Public Fund, L.P. (9.00%), Fhmlsp, L.L.C. (9.00%)
4,342,2669.00%13G (passive) amendmentDec 31, 2025
Patrick J. Heron
Joint filing with James N. Topper (9.40%), Albert Cha (9.00%) and 4 more
4,129,0009.40%13G (passive) amendmentMar 31, 2025
Kristina Burow
Joint filing with ARCH Venture Fund X, L.P. (9.40%), ARCH Venture Fund X Overage, L.P. (9.40%) and 6 more
4,120,0539.40%13G (passive)Mar 31, 2025
Deep Track Biotechnology Master Fund, Ltd.
Joint filing with Deep Track Capital, LP (9.02%), David Kroin (9.02%)
3,948,9109.02%13G (passive) amendmentJun 30, 2025
Fhmlsp, L.L.C.
Joint filing with Frazier Life Sciences Public Fund, L.P. (7.70%), Fhmlsp, L.P. (7.70%)
3,352,9157.70%13G (passive) amendmentJun 30, 2025
David Kroin
Joint filing with Deep Track Capital, LP (6.91%), Deep Track Biotechnology Master Fund, Ltd. (6.91%)
3,023,4846.91%13G (passive)Jan 31, 2025
BlackRock, Inc.2,978,1145.40%13G (passive)Jun 30, 2026
Janus Henderson Group PLC2,858,8765.80%13G (passive) amendmentMar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of MAZEValueChange% of portfolio
Frazier Life Sciences Management, L.P.5,032,9159.06%$150.18M+465,6413.27%
Trv Gp Iv, LLC4,473,9588.05%$133.50M–52.63%
ARCH Venture Management, LLC4,120,0537.42%$122.98M–11.18%
Deep Track Capital, LP3,732,5696.72%$111.38M+255,0071.62%
BlackRock, Inc.3,502,8416.31%$104.52M+932,4160.00%
Jupiter Topco LLC3,408,0456.14%$101.76MNew0.04%
T. Rowe Price Investment Management, Inc.2,603,6824.69%$77.69MNew0.05%
Logos Global Management LP1,935,0003.48%$57.74M+700,0002.49%
Vanguard Capital Management LLC1,778,2223.20%$53.06M+342,5660.00%
a16z Capital Management, L.L.C.1,702,2253.06%$50.79M–0.36%
VR Adviser, LLC1,602,0342.88%$47.80M–1.45%
Alphabet Inc.1,388,5832.50%$41.44M–0.04%
Braidwell LP1,140,0402.05%$34.02MNew1.26%
Farallon Capital Management LLC1,107,8141.99%$33.06M+734,8140.15%
FMR LLC1,056,9591.90%$31.54M+192,7450.00%
General Catalyst Group Management, LLC1,035,9101.86%$30.91M–16.40%
State Street Corp997,5331.80%$29.77M+360,8110.00%
JPMorgan Chase & Co964,0111.74%$28.00M+905,5650.00%
Driehaus Capital Management LLC954,8861.72%$28.49M+318,7240.17%
Trv Gp V, LLC950,8001.71%$28.37M–5.69%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202616259M100.0%39 / 6638 / 3917M8M
Q1 202616552M93.0%49 / 5836 / 2511M6M
Q4 202514348M87.1%57 / 4620 / 810M5M
Q3 20259443M77.4%23 / 3915 / 38M4M
Q2 20257539M69.9%14 / 2514 / 72M3M
Q1 20256840M72.1%68 / 00 / 040M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

174 funds held MAZE in Q2 2026, 46% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of MAZEValue% of fundAs of
Vanguard Total Stock Market Index Fund1,411,9902.54%$42.13M0.00%Jun 30, 2026
T. Rowe Price Capital Appreciation Fund978,3291.76%$29.19M0.04%Jun 30, 2026
iShares Russell 2000 ETF920,2841.66%$27.46M0.03%Jun 30, 2026
Select Biotechnology Portfolio739,6601.33%$19.57M0.37%May 31, 2026
JPMorgan Small Cap Growth Fund421,3500.76%$12.57M0.48%Jun 30, 2026
Fidelity Small Cap Index Fund385,6420.69%$10.38M0.03%Jul 31, 2026
Vanguard Extended Market Index Fund325,5130.59%$9.71M0.01%Jun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.295,4650.53%$8.82M0.09%Jun 30, 2026
iShares Russell 2000 Growth ETF276,0750.50%$8.24M0.05%Jun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.274,1850.49%$8.18M0.08%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF265,8300.48%$7.93M1.85%Jun 30, 2026
iShares Biotechnology ETF242,7630.44%$7.24M0.08%Jun 30, 2026
JNL/T. Rowe Price Capital Appreciation Fund212,2550.38%$6.33M0.04%Jun 30, 2026
BlackRock Health Sciences Opportunities Portfolio184,4530.33%$4.88M0.08%May 29, 2026
T. Rowe Price Institutional Small-Cap Stock Fund158,4150.29%$4.73M0.09%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jason V. ColomaChief Executive Officer, Director227,2280.41%Nov 4, 2026
Atul DandekarCSBO32,3160.06%Oct 30, 2026
Harold BernsteinPresident, R&D & CMO0–Oct 2, 2026
Phillips CourtneyGC and Corp. Secretary7,0070.01%Sep 4, 2026
Amy BachrodtSVP, Finance15,4650.03%Apr 2, 2026
Misbah TahirChief Financial Officer––Mar 3, 2026
Paula A. JohnsonDirector––Aug 17, 2026
Sophie KornowskiDirector––Aug 17, 2026
Richard H. SchellerDirector0–Jun 10, 2026
Herve HoppenotDirector––Jun 10, 2026
Jonathan E. LimDirector328,7000.59%Jun 10, 2026
Daniel K. SpiegelmanDirector––Jun 10, 2026
Charles J. HomcyDirector38,5350.07%Jun 10, 2026
Nancy C. AndrewsDirector––Jun 10, 2026
Neil KumarDirector––Mar 31, 2026
Catherine A. SohnDirector20,7440.04%Jan 8, 2026
Sekar KathiresanDirector103,7230.19%Sep 24, 2025
Neil ExterDirector––Sep 24, 2025
James BrushDirector––Jan 30, 2025
Jeffrey K. TongDirector––Jan 30, 2025
Alan ColowickDirector––Jan 30, 2025
Third Rock Ventures GP V, LP10% owner5,424,7589.77%Nov 5, 2025
Third Rock Ventures V, L.P.10% owner––Nov 5, 2025
Third Rock Ventures GP IV, L.P.10% owner––Nov 5, 2025
Trv Gp Iv, Llc10% owner––Nov 5, 2025
Third Rock Ventures IV, L.P.10% owner7,024,75812.65%Nov 5, 2025
Trv Gp V, Llc10% owner311,1700.56%Nov 5, 2025
Kristina Burow10% owner––Jan 30, 2025
Robert Nelsen10% owner––Jan 30, 2025
Steven Gillis10% owner––Jan 30, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jason V. Coloma
Chief Executive Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−5,345$31.05$165.98K186,901
Jason V. Coloma
Chief Executive Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−26,563$30.09$799.41K164,884
Jason V. Coloma
Chief Executive Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−336$30.91$10.39K12,965
Jason V. Coloma
Chief Executive Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−2,257$30.12$67.99K13,301
Atul Dandekar
CSBO
Oct 29, 2026Sale(10b5-1 plan)−7,500$32.07$240.53K32,316
Atul Dandekar
CSBO
Oct 29, 2026Option exercise+857$10.42$8.93K39,816
Atul Dandekar
CSBO
Oct 29, 2026Option exercise+6,643$10.42$69.22K38,959
Harold Bernstein
President, R&D & CMO
Oct 1, 2026Sale(10b5-1 plan)−16,141$26.93$434.74K0
Harold Bernstein
President, R&D & CMO
Oct 1, 2026Option exercise+16,141$10.42$168.19K16,141
Jason V. Coloma
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−31,908$27.02$862.19K191,447
Jason V. Coloma
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−2,593$27.02$70.07K15,558
Atul Dandekar
CSBO
Sep 29, 2026Sale(10b5-1 plan)−7,500$27.06$202.92K32,316
Atul Dandekar
CSBO
Sep 29, 2026Option exercise+7,500$10.42$78.15K39,816
Harold Bernstein
President, R&D & CMO
Sep 4, 2026Sale(10b5-1 plan)−9,705$26.22$254.47K0
Jason V. Coloma
Chief Executive Officer, Director
Sep 3, 2026Sale−11,282$26.01$293.44K27,491
Jason V. Coloma
Chief Executive Officer, Director
Sep 3, 2026Sale−129$25.77$3.32K27,362
Atul Dandekar
CSBO
Sep 3, 2026Sale−36$25.81$92932,316
Atul Dandekar
CSBO
Sep 3, 2026Sale−3,207$26.01$83.41K32,352
Phillips Courtney
GC and Corp. Secretary
Sep 3, 2026Sale−22$25.78$5677,007
Phillips Courtney
GC and Corp. Secretary
Sep 3, 2026Sale−1,990$26.01$51.76K7,029
Harold Bernstein
President, R&D & CMO
Sep 3, 2026Sale−5,130$26.01$133.43K9,764
Harold Bernstein
President, R&D & CMO
Sep 3, 2026Sale−59$25.78$1.52K9,705
Jason V. Coloma
Chief Executive Officer, Director
Sep 2, 2026Sale−9,852$26.38$259.90K40,148
Jason V. Coloma
Chief Executive Officer, Director
Sep 2, 2026Sale−1,375$27.12$37.29K38,773
Atul Dandekar
CSBO
Sep 2, 2026Sale−391$27.12$10.60K35,559
Atul Dandekar
CSBO
Sep 2, 2026Sale−2,800$26.38$73.86K35,950
Phillips Courtney
GC and Corp. Secretary
Sep 2, 2026Sale−1,738$26.38$45.85K9,262
Phillips Courtney
GC and Corp. Secretary
Sep 2, 2026Sale−243$27.12$6.59K9,019
Harold Bernstein
President, R&D & CMO
Sep 2, 2026Sale−4,481$26.38$118.21K15,519
Harold Bernstein
President, R&D & CMO
Sep 2, 2026Sale−625$27.12$16.95K14,894
Atul Dandekar
CSBO
Sep 1, 2026Option exercise+12,500––38,750
Jason V. Coloma
Chief Executive Officer, Director
Sep 1, 2026Sale(10b5-1 plan)−31,908$26.29$838.86K223,355
Jason V. Coloma
Chief Executive Officer, Director
Sep 1, 2026Option exercise+50,000––50,000
Jason V. Coloma
Chief Executive Officer, Director
Sep 1, 2026Sale(10b5-1 plan)−2,593$26.31$68.22K18,151
Phillips Courtney
GC and Corp. Secretary
Sep 1, 2026Option exercise+11,000––11,000
Harold Bernstein
President, R&D & CMO
Sep 1, 2026Option exercise+20,000––20,000
Harold Bernstein
President, R&D & CMO
Sep 1, 2026Sale(10b5-1 plan)−16,141$26.36$425.48K0
Harold Bernstein
President, R&D & CMO
Sep 1, 2026Option exercise+16,141$10.42$168.19K16,141
Atul Dandekar
CSBO
Aug 28, 2026Option exercise+7,500$10.42$78.15K33,750
Atul Dandekar
CSBO
Aug 28, 2026Sale(10b5-1 plan)−7,500$27.58$206.85K26,250
Harold Bernstein
President, R&D & CMO
Aug 13, 2026Option exercise+16,142$10.42$168.20K16,142
Harold Bernstein
President, R&D & CMO
Aug 13, 2026Sale(10b5-1 plan)−16,142$27.61$445.68K0
Jason V. Coloma
Chief Executive Officer, Director
Aug 3, 2026Sale(10b5-1 plan)−1,604$27.09$43.45K255,263
Jason V. Coloma
Chief Executive Officer, Director
Aug 3, 2026Sale(10b5-1 plan)−30,304$26.71$809.42K256,867
Jason V. Coloma
Chief Executive Officer, Director
Aug 3, 2026Sale(10b5-1 plan)−154$27.09$4.17K20,744
Jason V. Coloma
Chief Executive Officer, Director
Aug 3, 2026Sale(10b5-1 plan)−2,439$26.71$65.15K20,898
Atul Dandekar
CSBO
Jul 29, 2026Sale(10b5-1 plan)−7,100$27.31$193.90K26,650
Atul Dandekar
CSBO
Jul 29, 2026Sale(10b5-1 plan)−400$27.89$11.16K26,250
Atul Dandekar
CSBO
Jul 29, 2026Option exercise+7,500$10.42$78.15K33,750
Jason V. Coloma
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−30,311$29.95$907.81K288,768
Jason V. Coloma
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−2,593$29.98$77.74K23,337
Jason V. Coloma
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−1,597$30.44$48.61K287,171
Harold Bernstein
President, R&D & CMO
Jul 1, 2026Sale(10b5-1 plan)−13,409$29.87$400.53K1,200
Harold Bernstein
President, R&D & CMO
Jul 1, 2026Option exercise+14,609$10.42$152.23K14,609
Harold Bernstein
President, R&D & CMO
Jul 1, 2026Sale(10b5-1 plan)−1,200$30.34$36.41K0
Atul Dandekar
CSBO
Jun 29, 2026Option exercise+7,500$10.42$78.15K33,750
Atul Dandekar
CSBO
Jun 29, 2026Sale(10b5-1 plan)−7,500$28.02$210.15K26,250
Jason V. Coloma
Chief Executive Officer, Director
Jun 23, 2026Sale(10b5-1 plan)−23,865$26.05$621.68K319,079
Jason V. Coloma
Chief Executive Officer, Director
Jun 22, 2026Sale(10b5-1 plan)−2,040$26.00$53.04K25,930
Jason V. Coloma
Chief Executive Officer, Director
Jun 22, 2026Sale(10b5-1 plan)−1,953$26.00$50.78K342,944

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
14.47%
7M shares short
Days to cover
8.8
At 1M shares a day
Change since last report
-11.2%
From 8M shares
Short volume, 20 days
58.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Maze Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,859 shares on Sep 16, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Jason V. Coloma
Officer
Nov 2, 202634,501$1.09MNov 2, 2026Gift
Atul Dandekar
Officer
Oct 29, 202615,000$475.95KOct 29, 2026Exercise of Stock Options
Jason V. Coloma
Officer
Oct 1, 202634,501$933.25KOct 1, 2026Gift
Harold Bernstein
Officer
Oct 1, 202616,141$438.71KOct 1, 2026Exercise of Stock Options
Harold Bernstein
Officer
Sep 4, 20269,705$251.07KSep 4, 2026Restricted Stock Units
Phillips Courtney
Officer
Sep 2, 20264,144$110.00KSep 2, 2026Restricted Stock Unit Vesting
Atul Dandekar
Officer
Sep 2, 20266,679$177.20KSep 2, 2026Restricted Stock Unit Vesting
Jason V. Coloma
Officer
Sep 2, 202623,497$623.40KSep 2, 2026Restricted Stock Unit Vesting
Harold Bernstein
Officer
Sep 2, 202610,685$283.50KSep 2, 2026Restricted Stock Unit Vesting
Jason V. Coloma
Officer
Sep 1, 202634,501$908.07KSep 1, 2026Gift
Jason V. Coloma
Officer
Aug 3, 202634,501$922.56KAug 3, 2026Gift
Atul Dandekar
Officer
Jul 29, 202622,500$627.30KJul 29, 2026Exercise of Stock Options
Harold Bernstein
Officer
Jul 1, 202646,892$1.40MJul 1, 2026Exercise of Stock Options
Jason V. Coloma
Officer
Jul 1, 202634,501$1.03MJul 1, 2026Gift
Jason V. Coloma
Officer
Jun 1, 202634,501$908.07KJun 1, 2026Gift

See a number that looks wrong?